Table 2.

Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause in relation to tumor composite scores for cytotoxic T lymphocytes (CTL) and granzyme B (GZMB) in the CRC patients, IWHS, 1986-2011.

Composite score	All-cause death
	No. Deathsb	Person-years	HR (95% CI)c	HR (95% CI)d	HR (95% CI)e	HR (95% CI)f
CTLa	n=313
2-3.9	76	745	Reference	Reference	Reference	Reference
4-5.1	100	1089	0.92 (0.68-1.23)	0.72 (0.53-0.99)	0.75 (0.54-1.05)	0.74 (0.54-1.01)
5.2-6.3	72	1040	0.69 (0.50-0.96)	0.68 (0.49-0.95)	0.67 (0.46-0.98)	0.76 (0.53-1.07)
>6.3	65	1017	0.64 (0.46-0.90)	0.53 (0.38-0.75)	0.49 (0.32-0.73)	0.62 (0.41-0.94)
P-trend			0.002	0.0004	0.0006	0.04
GZMB a	n=310
2	146	1518	Reference	Reference	Reference	Reference
2.2-2.8	100	744	0.81 (0.59-1.09)	0.82 (0.60-1.12)	0.76 (0.54-1.07)	0.84 (0.61-1.15)
>3	64	1544	0.72 (0.56-0.92)	0.66 (0.51-0.86)	0.64 (0.46-0.89)	0.78 (0.56-1.09)
P-trend			0.009	0.002	0.01	0.12
Joint score for CTLs and GZMB g	n=309
0	56	500	Reference	Reference	Reference
1	199	2443	0.74 (0.55-1.00)	0.70 (0.52-0.98)	0.71 (0.51-0.99)
2	54	825	0.60 (0.41-0.87)	0.50 (0.34-0.73)	0.47 (0.30-0.74)
P-trend			<0.0001	<0.0001	0.001

^aTumor CTL and GZMB composite scores were created as a sum of corresponding epithelial and stromal scores categorized into quartiles for CTL and tertiles for GZMB.

^bThe number of deaths is slightly different in the analyses of CTL and GZMB because of different number of available cores (n=465 for CTL and n=458 for GZMB; overall 468 CRC patients had tissues immunostained for CTL or GZMB.

^cModel 1: Unadjusted.

^dModel 2: Model adjusted for age at diagnosis, BMI, smoking status, stage and grade at diagnosis.

^eModel 3: Model 2 + integrated pathway.

^fBoth GZMB and CTL tumor composite scores were included with all variables in Model 2.

^gJoint score for GZMB and CTL tumor composite scores was created as follows: 0 – lowest categories of CTL and GZMB; 2 – highest categories of CTL and GZMB; and 1 – all other combinations.